Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.065 AUD | -8.45% | -12.16% | -5.80% |
Apr. 17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
Apr. 17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
Sales 2022 | 608K 405K | Sales 2023 | 1.19M 796K | Capitalization | 34.96M 23.29M |
---|---|---|---|---|---|
Net income 2022 | -3M -2M | Net income 2023 | -7M -4.66M | EV / Sales 2022 | 77.3 x |
Net cash position 2022 | 1.9M 1.26M | Net cash position 2023 | 5.03M 3.35M | EV / Sales 2023 | 25.1 x |
P/E ratio 2022 |
-14.5
x | P/E ratio 2023 |
-4.1
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.23% |
1 day | -8.45% | ||
1 week | -12.16% | ||
Current month | -8.45% | ||
1 month | -20.73% | ||
3 months | -35.00% | ||
6 months | +12.07% | ||
Current year | -5.80% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Operating Officer | - | 22-03-07 | |
Erlyn Dawson
SEC | Corporate Secretary | - | 19-04-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Davies
CHM | Chairman | - | 19-04-15 |
Thomas Duthy
BRD | Director/Board Member | - | 22-08-31 |
Gerald Quigley
BRD | Director/Board Member | - | 22-07-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 0.065 | -8.45% | 3 296 116 |
24-05-31 | 0.071 | -1.39% | 510,942 |
24-05-30 | 0.072 | -1.37% | 219,219 |
24-05-29 | 0.073 | 0.00% | 447,357 |
24-05-28 | 0.073 | -1.35% | 316,838 |
Delayed Quote Australian S.E., June 03, 2024 at 01:55 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-5.80% | 47.96M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.35% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- NTI Stock